<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="evidence" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="span">3. Discussion</segment>
<segment id="2" parent="1" relname="elaboration">Identified mechanisms for target molecule elevation in CKD patients are either a decrease in renal excretion , an increase in endogenous production or both .</segment>
<segment id="3" parent="1004" relname="span">Thus , TMAO levels could result from variations in production levels</segment>
<segment id="4" parent="3" relname="elaboration">( including dietary precursor intake , TMA endogenous production from gut microbiota , TMA and TMAO intestinal absorption , and FMO3 enzymatic activity )</segment>
<segment id="5" parent="1003" relname="same_unit">or from its renal excretion .</segment>
<segment id="6" parent="1006" relname="span">This study was therefore designed</segment>
<segment id="7" parent="1007" relname="span">to assess the exact changes in TMAO values</segment>
<segment id="8" parent="9" relname="attribution">according to CKD stages</segment>
<segment id="9" parent="1008" relname="span">as determined by gold standard measurements of GFR and its potential modifications during renal metabolism .</segment>
<segment id="10" parent="1011" relname="attribution">In the present study , we confirmed</segment>
<segment id="11" parent="1011" relname="span">that TMAO is increased in CKD</segment>
<segment id="12" parent="1012" relname="span">based on an inverse , although weak , correlation</segment>
<segment id="13" parent="12" relname="restatement">( r2 = 0.388 ) between plasma TMAO and mGFR .</segment>
<segment id="14" parent="1014" relname="span">Surprisingly , in all stages of CKD , we did not find any correlation between TMAO levels and its precursors , except a weak correlation with carnitine .</segment>
<segment id="15" parent="14" relname="elaboration">Measured clearances of TMAO showed a complete renal excretion of TMAO by glomerular filtration with a steady FE of 105 % during CKD , regardless of the stage .</segment>
<segment id="16" parent="1015" relname="joint">Unlike previous studies , we reported no evidence for effective contribution of tubular excretion or reabsorption during renal clearance of TMAO .</segment>
<segment id="17" parent="1017" relname="span">In hemodialysis patients , we confirmed a greater increase in TMAO</segment>
<segment id="18" parent="17" relname="concession">even though FR was similar to that of urea .</segment>
<segment id="19" parent="1019" relname="span">This study investigated for the first time TMAO levels in all stages of CKD</segment>
<segment id="20" parent="19" relname="means">using gold standard measures of GFR .</segment>
<segment id="21" parent="1020" relname="joint">Results of TMAO plasma concentrations in CKD were in good accordance with previous studies .</segment>
<segment id="22" parent="1025" relname="span">Median TMAO plasma levels</segment>
<segment id="23" parent="22" relname="elaboration">found herein</segment>
<segment id="24" parent="1024" relname="same_unit">were similar to those</segment>
<segment id="25" parent="1024" relname="elaboration">published by Stubbs et al. in 2015 ,</segment>
<segment id="26" parent="1023" relname="concession">even though their data was based on estimated GFR .</segment>
<segment id="27" parent="28" relname="concession">Another study reported a negative correlation between TMAO and mGFR</segment>
<segment id="28" parent="1027" relname="span">but both data sets were restricted to CKD stages 3 or more severe .</segment>
<segment id="29" parent="1028" relname="joint">To the best of our knowledge , no study has performed urinary clearance measures of TMAO in CKD .</segment>
<segment id="30" parent="1030" relname="span">Previously , Hai et al. published TMAO clearances in control subjects ,</segment>
<segment id="31" parent="1031" relname="span">reporting a higher clearance of TMAO compared to creatinine ,</segment>
<segment id="32" parent="31" relname="elaboration">suggesting an active secretion of TMAO .</segment>
<segment id="33" parent="1034" relname="span">Due to its low molecular weight</segment>
<segment id="34" parent="33" relname="restatement">( 75 Da )</segment>
<segment id="35" parent="1033" relname="same_unit">and soluble non ionizable nature , with minimal protein-bound fraction ,</segment>
<segment id="36" parent="1036" relname="preparation">we consider</segment>
<segment id="37" parent="1037" relname="span">TMAO to be entirely filtered through the glomerular basement membrane ,</segment>
<segment id="38" parent="37" relname="elaboration">which is the main known elimination route for TMAO .</segment>
<segment id="39" parent="1038" relname="joint">Our results showed a likely complete TMAO glomerular filtration with a steady FE of TMAO , regardless of CKD stages .</segment>
<segment id="40" parent="1040" relname="span">TMAO clearance was similar to that of mGFR , higher than that of urea , and lower than that of creatinine ,</segment>
<segment id="41" parent="1042" relname="attribution">suggesting</segment>
<segment id="42" parent="1042" relname="joint">that TMAO is neither secreted as creatinine</segment>
<segment id="43" parent="1042" relname="joint">nor reabsorbed as urea by renal tubules .</segment>
<segment id="44" parent="45" relname="attribution">We however cannot exclude</segment>
<segment id="45" parent="1044" relname="span">that the secretion rate exactly matched the reabsorption of TMAO .</segment>
<segment id="46" parent="1047" relname="attribution">Furthermore , high fractional reabsorption of sodium indicates</segment>
<segment id="47" parent="1047" relname="span">that study participants had no tubular impairment ,</segment>
<segment id="48" parent="47" relname="elaboration">which reinforces the validity of these data .</segment>
<segment id="49" parent="1050" relname="attribution">However , the IQR of TMAO FE showed</segment>
<segment id="50" parent="1051" relname="span">that some patients exhibited higher or lower clearances of TMAO</segment>
<segment id="51" parent="50" relname="elaboration">compared to mGFR ;</segment>
<segment id="52" parent="1053" relname="span">especially in the control group</segment>
<segment id="53" parent="52" relname="elaboration">where the median FE of TMAO was 103 %</segment>
<segment id="54" parent="1053" relname="evidence">[ IQR 55 â€“ 144 ] .</segment>
<segment id="55" parent="1054" relname="joint">This dispersion could be explained by several factors .</segment>
<segment id="56" parent="1056" relname="span">First , urinary clearance of TMAO was not assessed at the exact same time points than mGFR ,</segment>
<segment id="57" parent="56" relname="elaboration">measured by inulin or iohexol clearance .</segment>
<segment id="58" parent="1057" relname="joint">Second , the variability of TMAO excretion could also be related to the amount of ingested TMA precursors .</segment>
<segment id="59" parent="1059" relname="span">We unfortunately did not administer standardized meals</segment>
<segment id="60" parent="59" relname="purpose">to avoid this bias .</segment>
<segment id="61" parent="1060" relname="joint">Yet , we did not find a significant correlation between plasma levels of TMAO and total protein intake .</segment>
<segment id="62" parent="1062" relname="span">Moreover , several studies in animal or cellular models have shown involvement of tubular transporters such as organic cation transporter 2</segment>
<segment id="63" parent="1063" relname="same_unit">( OCT2 )</segment>
<segment id="64" parent="1063" relname="same_unit">in TMAO cellular uptake and efflux .</segment>
<segment id="65" parent="1065" relname="span">This , however , has not been confirmed in humans</segment>
<segment id="66" parent="65" relname="elaboration">unlike what has been previously described for creatinine .</segment>
<segment id="67" parent="68" relname="attribution">We observed</segment>
<segment id="68" parent="1067" relname="span">that elevation of TMAO is mostly due to a decrease in mGFR rather than tubular dysfunction .</segment>
<segment id="69" parent="1068" relname="span">These results are in line with another recent study</segment>
<segment id="70" parent="1071" relname="attribution">reporting</segment>
<segment id="71" parent="1071" relname="span">that urinary TMAO/creatinine ratios</segment>
<segment id="72" parent="71" relname="elaboration">( used as a surrogate of TMAO excretion rate )</segment>
<segment id="73" parent="1069" relname="same_unit">were not significantly different between control and CKD subjects .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1002" relname="preparation"/>
<group id="1002" type="span" parent="1000" relname="span"/>
<group id="1003" type="multinuc" parent="1005" relname="preparation"/>
<group id="1004" type="span" parent="1003" relname="same_unit"/>
<group id="1005" type="multinuc" parent="1002" relname="span"/>
<group id="1006" type="span" parent="1005" relname="joint"/>
<group id="1007" type="span" parent="6" relname="purpose"/>
<group id="1008" type="span" parent="7" relname="elaboration"/>
<group id="1010" type="span" parent="1005" relname="joint"/>
<group id="1011" type="span" parent="1010" relname="span"/>
<group id="1012" type="span" parent="11" relname="elaboration"/>
<group id="1013" type="span" parent="1005" relname="joint"/>
<group id="1014" type="span" parent="1013" relname="span"/>
<group id="1015" type="multinuc" parent="1014" relname="elaboration"/>
<group id="1016" type="multinuc" parent="1015" relname="joint"/>
<group id="1017" type="span" parent="1016" relname="joint"/>
<group id="1018" type="multinuc" parent="1016" relname="joint"/>
<group id="1019" type="span" parent="1018" relname="joint"/>
<group id="1020" type="multinuc" parent="1018" relname="joint"/>
<group id="1021" type="multinuc" parent="1020" relname="joint"/>
<group id="1022" type="span" parent="1021" relname="joint"/>
<group id="1023" type="span" parent="1022" relname="span"/>
<group id="1024" type="multinuc" parent="1023" relname="span"/>
<group id="1025" type="span" parent="1024" relname="same_unit"/>
<group id="1026" type="multinuc" parent="1021" relname="joint"/>
<group id="1027" type="span" parent="1026" relname="joint"/>
<group id="1028" type="multinuc" parent="1026" relname="joint"/>
<group id="1029" type="multinuc" parent="1028" relname="joint"/>
<group id="1030" type="span" parent="1029" relname="joint"/>
<group id="1031" type="span" parent="30" relname="elaboration"/>
<group id="1032" type="span" parent="1029" relname="joint"/>
<group id="1033" type="multinuc" parent="1035" relname="preparation"/>
<group id="1034" type="span" parent="1033" relname="same_unit"/>
<group id="1035" type="span" parent="1032" relname="span"/>
<group id="1036" type="multinuc" parent="1035" relname="span"/>
<group id="1037" type="span" parent="1036" relname="joint"/>
<group id="1038" type="multinuc" parent="1036" relname="joint"/>
<group id="1039" type="multinuc" parent="1038" relname="joint"/>
<group id="1040" type="span" parent="1039" relname="joint"/>
<group id="1041" type="span" parent="40" relname="elaboration"/>
<group id="1042" type="multinuc" parent="1041" relname="span"/>
<group id="1043" type="multinuc" parent="1039" relname="joint"/>
<group id="1044" type="span" parent="1043" relname="joint"/>
<group id="1045" type="multinuc" parent="1043" relname="joint"/>
<group id="1046" type="span" parent="1045" relname="joint"/>
<group id="1047" type="span" parent="1046" relname="span"/>
<group id="1048" type="multinuc" parent="1045" relname="joint"/>
<group id="1049" type="span" parent="1048" relname="joint"/>
<group id="1050" type="span" parent="1049" relname="span"/>
<group id="1051" type="span" parent="1050" relname="span"/>
<group id="1052" type="span" parent="1051" relname="circumstance"/>
<group id="1053" type="span" parent="1052" relname="span"/>
<group id="1054" type="multinuc" parent="1048" relname="joint"/>
<group id="1055" type="multinuc" parent="1054" relname="joint"/>
<group id="1056" type="span" parent="1055" relname="joint"/>
<group id="1057" type="multinuc" parent="1055" relname="joint"/>
<group id="1058" type="multinuc" parent="1057" relname="joint"/>
<group id="1059" type="span" parent="1058" relname="joint"/>
<group id="1060" type="multinuc" parent="1058" relname="joint"/>
<group id="1061" type="multinuc" parent="1060" relname="joint"/>
<group id="1062" type="span" parent="1061" relname="joint"/>
<group id="1063" type="multinuc" parent="62" relname="evidence"/>
<group id="1064" type="multinuc" parent="1061" relname="joint"/>
<group id="1065" type="span" parent="1064" relname="joint"/>
<group id="1066" type="multinuc" parent="1064" relname="joint"/>
<group id="1067" type="span" parent="1066" relname="joint"/>
<group id="1068" type="span" parent="1066" relname="joint"/>
<group id="1069" type="multinuc" parent="69" relname="elaboration"/>
<group id="1070" type="span" parent="1069" relname="same_unit"/>
<group id="1071" type="span" parent="1070" relname="span"/>
	</body>
</rst>
